SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-19-022087
Filing Date
2019-04-30
Accepted
2019-04-30 06:30:20
Documents
6
Period of Report
2019-06-12
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A tv519718-def14a.htm DEF 14A 352954
2 GRAPHIC lg_checkpoint-therapeutics.jpg GRAPHIC 35378
3 GRAPHIC sg_garrett-gray.jpg GRAPHIC 53982
4 GRAPHIC sg_james-oliviero.jpg GRAPHIC 11462
5 GRAPHIC tv519718_pc1.jpg GRAPHIC 552756
6 GRAPHIC tv519718_pc2.jpg GRAPHIC 541542
  Complete submission text file 0001144204-19-022087.txt   2000425
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38128 | Film No.: 19778296
SIC: 2834 Pharmaceutical Preparations